10.15.26 -- The CDMO's Perspective: Audience Q&A With Thermo Fisher Scientific

See how disciplined containment, proactive risk management, and collaboration accelerate oncology programs under tight timelines while protecting quality, safety, and global launch readiness.

To align with Annex 1 expectations, sponsors should focus on three key steps: understanding the guidelines, selecting the right partners, and futureproofing their manufacturing strategies.

Evolving biosimilar guidance creates opportunities to reduce comparative clinical requirements through strong analytical evidence, risk-based justification, structure-function knowledge, and more.

Working with a partner that provides a one-stop shop for bioconjugate development and manufacturing helps prevent missteps that threaten the delivery of life-saving drugs to patients who need them.

Biologics are growing more complex. But what if the syringe itself could unlock new possibilities? Discover the technology “bricks” quietly reshaping subcutaneous drug delivery.

Explore the potential of targeting LILRB2/LILRB4 in cancer immunotherapy by delving into our findings on novel monoclonal antibodies that enhance anti-tumor immune responses.

Only 6.7% of Phase 1 drugs reach approval. A well-structured Drug Development Plan (DDP) can meaningfully improve your odds — learn exactly how to build one.

Leveraging cross-functional coordination between sites, harmonized tech transfers, one quality system, and synchronized team activities can streamline regulatory submissions.